JPMorgan analyst Yang Huang initiated coverage of Ascentage Pharma (AAPG) with an Overweight rating and HK$52 price target The company’s Olverembatinib, having been approved for three CML ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
As global markets experience a period of optimism fueled by easing core inflation and robust earnings in the financial sector, investors are eyeing opportunities in smaller companies that have ...
Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...
He worked at a number of leading pharma companies in Hong Kong, including Jacobson Pharma Group and Wai Yuen Tong, before joining Vita Green in 2018, building a breadth of experience within ...
LAKE WISSOTA, Wis. (WEAU) - Jacobson’s Market announced that they would be taking over the liquor store portion of the Family Fare Liquor Store. According to a Facebook post, they will be ...
4d
News-Medical.Net on MSNAI-powered therapy chatbot shows significant mental health benefitsDartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, ...
BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the ...
The Lodge Bar & Grill at Jacobson Plaza opens April 30th. “Anything from smash burgers, to sandwiches, some shareable options,” The Lodge Wolf said. While, the facility is city-owned ...
Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results